|分野（sector）||Health Care ヘルスケア|
|概要||事業概要 -- PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The firm conducts its operations in four divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy and Emerging Innovations. The GI Health division consists of Edouard Esophageal DNA Test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus Technology. The Minimally Invasive Interventions division consists of CarpX, which is a patented, single-use disposable, minimally invasive device designed to treat carpal tunnel syndrome. The Infusion Therapy division consists of PortIO, which is a novel, patented, implantable, intraosseous vascular medical device; and NextFlo, which is designed to deliver gravity-driven infusions independent of the height of the IV bag. The Emerging Innovations division refers to a diversified and expanding portfolio of innovative products designed to address unmet clinical needs across a broad range of clinical conditions. The company was founded on June 26, 2014 and is headquartered in New York, NY.|
Founder and Former Chairman & CEO of Exact Sciences Stanley Lapidus Joins PAVmed Subsidiary Lucid Diagnostics as Strategic Advisor 2020/06/15 13:30:00 GlobeNewswire
NEW YORK, June 15, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multiproduct medical…
Canon Virginia Partners with PAVmed to Manufacture Resorbable Pediatric Ear Tubes 2020/06/04 13:44:17 PlasticsToday
Medical device company PAVmed Inc. has announced that it will partner with Canon Virginia Inc. to manufacture its resorbable DisappEAR molded pediatric ear tubes. A letter of intent articulates the agreement between the companies to use Canon Virginia’s commercial-grade, scalable aqueous silk fibroin molding process to produce the ear tubes. Initially, PAVmed was machining blocks of silk but has decided to transition to injection molding because, as the company said in a press release, it is “a much less costly and efficient commercial manufacturing process, especially at scale.” Conventional pediatric ear tubes can dislodge and fall into the ear canal, creating a wax buildup that can increase risk of infection. Image was captured from a video, embedded below, provided by PAVmed. PAVmed chose Canon Virginia as its partner for this project because of its wealth of relevant manufacturing expertise and capabilities. “Canon’s extensive experience and expertise in innovative and efficient production methods and its vast state-of-the-art facilities in Newport News, Virginia, make it the ideal partner to develop this groundbreaking technology for the one million children who currently undergo ear tube placement each year,” said said Lishan Aklog, MD, PAVmed Chairman and CEO.
関連キーワード （― 米国株 PAVMW PAVmed Inc.）